Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Lomtadze, Nino ^a   Kupreishvili, Lali ^a   Salakaia, Archil ^a   Vashakidze, Sergo ^a   Sharvadze, Lali ^b   Kempker, Russell R ^c   Magee, Matthew J ^d   Del Rio, Carlos ^c,d   Blumberg, Henry M ^c,d  

^a National Center for Tuberculosis and Lung Diseases   (Georgia)

^b Infectious Diseases AIDS and Clinical Immunology Research Center   (Georgia)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SHORT COURSE THERAPY; AGED; COMPLICATION; DRUG EFFECTS; GENETICS; GEORGIA; HIV INFECTIONS; LIVER; MIDDLE AGED; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; COINFECTION; FEMALE; GEORGIA; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84893201221     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083892     Document Type: Article

References (29)

1. World Health Organization (2013) Global Tuberculosis Report 2013 Geneva; World Health Organization, WHO /HTM/TB/2013.11
2. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362: 887-899. doi:10.1016/S0140-6736(03)14333-4. (Pubitemid 37130100)
3. Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, Khechinashvili G et al. (2001) Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J Tuberc Lung Dis 5: 164-169. PubMed: 11258510. (Pubitemid 32401861)
4. Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A et al. (2009) Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 13: 68-73. PubMed: 19105881.
5. Lawn SD, Zumla AI (2011) Tuberculosis. Lancet 378: 57-72. doi:10.1016/S0140-6736(10)62173-3.
6. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization. WHO/HTM/TB/2010.3
7. World Health Organization (1999) Global surveillance and control of hepatitis C: Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47. doi:10.1046/j.1365-2893.1999.6120139.x. PubMed: 10847128.
8. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. doi:10.1016/S1473-3099(05)70216- 4. PubMed: 16122679. (Pubitemid 41196755)
9. Zaller N, Nelson KE, Aladashvili M, Badridze N, del Rio C et al. (2004) Risk Factors for Hepatitis C Virus Infection among Blood Donors in Georgia. Eur J Epidemiol 19: 547-553. PubMed: 15330127. (Pubitemid 39005416)
10. Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson JCE et al. (2006) High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. International Journal of Tuberculosis and Lung Disease 10: 396-401. PubMed: 16602403.
11. Butsashvili M, Tsertsvadze T, McNutt LA, Kamkamidze G, Gvetadze R et al. (2001) Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors. Eur J Epidemiol 17: 693-695. doi:10.1023/A:1015566132757. PubMed: 12086085. (Pubitemid 34602362)
12. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D et al. (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157: 1871-1876. doi:10.1164/ajrccm.157.6.9711039. PubMed: 9620920.
13. Park WB, Kim W, Lee KL, Yim JJ, Kim M et al. (2010) Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 61: 323-329. doi:10.1016/j.jinf.2010.07.009. PubMed: 20670648.
14. Tuberculosis Coalition for Technical Assistance (2009) International Standards for Tuberculosis Care (ISTC), second edition. The Hague: Tuberculosis Coalition for Technical Assistance.
15. World Health Organization (2010) Treatment of tuberculosis guidelines, 4th ed. Geneva, Switzerland: WHO Press. WHO/HTM/TB/2009.420
16. Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN et al. (2011) Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 24: 314-350. doi:10.1128/CMR.00059-10. PubMed: 21482728.
17. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK et al. (2012) Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLOS ONE 7: e31563. doi:10.1371/journal.pone.0031563. PubMed: 22347495.
18. World Health Organization (2009) Guidelines for surveillance of drug resistance in tuberculosis - 4th edition. Geneva: World Health Organization. WHO/HTM/TB/2009.422
19. Karchava M, Sharvadze L, Gatserelia L, Badridze N, Tsertsvadze T (2009) Prevailing HCV genotypes and subtypes among hiv infected patients in Georgia. Georgian Med News: 51-55. PubMed: 20090154.
20. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J et al. (2002) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 137: 640-647. doi:10.7326/0003-4819-137-8-200210150-00007. PubMed: 12379063. (Pubitemid 35176096)
21. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL et al. (2011) Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 62: 448-455. doi:10.1016/j.jinf.2011.04.005. PubMed: 21570123.
22. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H et al. (2007) Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 131: 803-808. doi:10.1378/chest.06-2042. PubMed: 17356096. (Pubitemid 46446873)
23. Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ et al. (2010) Hepatitis C virus infection increases hepatitis risk during antituberculosis treatment. Int J Tuberc Lung Dis 14: 616-621. PubMed: 20392356.
24. Lauer GM, Walker BD (2001) Hepatitis C Virus. Infection - New England Journal of Medicine 345: 41-52. doi:10.1056/NEJM200107053450107.
25. Shapatava E NK, Tsertsvadze T, del Rio C (2006) Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 82: S35-S38. doi:10.1016/S0376-8716(06)80006-2. PubMed: 16769443. (Pubitemid 43850175)
26. Jafari S, Copes R, Baharlou S, Etminan M, Buxton J (2010) Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 14: e928-e940. doi:10.1016/j.ijid.2010.03.019. PubMed: 20678951.
27. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192-202. doi:10.1111/j.1440-1746.2007.05207.x. PubMed: 17995946. (Pubitemid 351257678)
28. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I et al. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477. doi:10.1164/rccm.200206-626OC. PubMed: 12569078. (Pubitemid 37363354)
29. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662. doi:10.1164/rccm.167.4.603. PubMed: 12588714.